For Health Care Professionals Outside the US

 
 
 

Patient characteristics and baseline demographics in patients previously treated with bortezomib (BTZ) and an immunomodulatory drug (IMiD)1

Reference:

  1. San-Miguel J, Hungria VTM, Yoon S, et al. Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: a predefined subgroup analysis of PANORAMA 1. Presented at: ASCO 2015; May 29-June 2, 2015; Chicago, IL.

Ready to prescribe? Create a custom medicine tracker calendar for your patient

';